Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL458920 | 0.98 | SIGMAR1 (0.31) | SIGMAR1 | |
| SCHEMBL31566566 | 0.86 | — | — | |
| SCHEMBL31566527 | 0.86 | — | — | |
| SCHEMBL9175623 | 0.86 | — | — | |
| Hydrochloric Acid SCHEMBL31566984 | 0.85 | TSHR (0.31) | — | |
| SCHEMBL15076441 | 0.82 | SIGMAR1 (0.30) | SIGMAR1 | |
| SCHEMBL2688537 | 0.82 | — | — | |
| Tert-Butyl Formate SCHEMBL28325448 | 0.81 | TDP1 (0.41) | — | |
| SCHEMBL2941966 | 0.78 | — | — | |
| SCHEMBL5831867 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4027995-B1 | HPK1 ANTAGONISTS AND USES THEREOF | NIMBUS SATURN INC (US) | 2026-05-27 | — | — | EP | disclosed |
| US-20260116881-A1 | KIF MODULATOR COMPOUNDS AND METHODS OF USE | IAMBIC THERAPEUTICS INC (US) | 2026-04-30 | — | — | US | disclosed |
| EP-4647431-A1 | COMPOUND AND METHOD FOR TARGETED DEGRADATION OF ANDROGEN RECEPTOR | Gan & lee Pharm Co., Ltd. (CN) | 2025-11-12 | — | — | EP | disclosed |
| US-20250289801-A1 | EGFR INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2025-09-18 | — | — | US | disclosed |
| CN-119874700-A | HPK1 antagonists and uses thereof | 林伯士萨顿公司 | 2025-04-25 | — | — | CN | disclosed |
| CN-115135642-B | Inhibitors of EGFR mutant forms | 缆图药品公司 | 2025-03-04 | — | — | CN | disclosed |
| US-12215105-B2 | HPK1 antagonists and uses thereof | Nimbus Saturn, Inc. (US) | 2025-02-04 | — | — | US | disclosed |
| CN-114945366-B | HPK1 antagonists and uses thereof | 林伯士萨顿公司 | 2025-01-07 | — | — | CN | disclosed |
| US-12172983-B2 | EGFR inhibitors | BLUEPRINT MEDICINES CORPORATION (US) | 2024-12-24 | — | — | US | disclosed |
| WO-2024146617-A1 | COMPOUND AND METHOD FOR TARGETED DEGRADATION OF ANDROGEN RECEPTOR | 甘李药业股份有限公司 | 2024-07-11 | — | — | WO | disclosed |
| US-8993771-B2 | Hepatitis B antiviral agents | NOVIRA THERAPEUTICS, INC. (US) | 2015-03-31 | — | — | US | disclosed |
| WO-2014165128-A2 | HEPATITIS B ANTIVIRAL AGENTS | NOVIRA THERAPEUTICS, INC. (US) | 2014-10-09 | — | — | WO | disclosed |
| US-20140275167-A1 | HEPATITIS B ANTIVIRAL AGENTS | NOVIRA THERAPEUTICS, INC. | 2014-09-18 | — | — | US | disclosed |
| US-20140275167-A1 | HEPATITIS B ANTIVIRAL AGENTS | NOVIRA THERAPEUTICS, INC. | 2014-09-18 | — | — | US | disclosed |
| US-8822688-B2 | Imidazo[1,2-a]pyridine derivative | ASTELLAS PHARMA INC. (JP) | 2014-09-02 | — | — | US | disclosed |
| US-8822688-B2 | Imidazo[1,2-a]pyridine derivative | ASTELLAS PHARMA INC. (JP) | 2014-09-02 | — | — | US | disclosed |
| WO-2014081718-A1 | AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS | GENENTECH, INC. (US) | 2014-05-30 | — | — | WO | disclosed |
| US-20130053363-A1 | IMIDAZO[1,2-a]PYRIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2013-02-28 | — | — | US | disclosed |
| US-20130053363-A1 | IMIDAZO[1,2-a]PYRIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2013-02-28 | — | — | US | disclosed |
| WO-2011136192-A1 | IMIDAZO[1,2-a]PYRIDINE DERIVATIVE | アステラス製薬株式会社 (JP) | 2011-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260116881-A1 | KIF MODULATOR COMPOUNDS AND METHODS OF USE | KIF2C, KIF5B, KIF5C | SIGMAR1 272/4885 |
| US-20140275167-A1 | HEPATITIS B ANTIVIRAL AGENTS | HAVCR2, EIF2AK2, MAVS | SIGMAR1 2085/4885 |
| US-12172983-B2 | EGFR inhibitors | EGFR, ERBB2, ERBB3 | SIGMAR1 2308/4885 |
| US-20250289801-A1 | EGFR INHIBITORS | EGFR, ERBB2, ERBB3 | SIGMAR1 2308/4885 |
| US-20130053363-A1 | IMIDAZO[1,2-a]PYRIDINE DERIVATIVE | PDE4B, PDE4A, PDE4C | SIGMAR1 3645/4885 |
| US-12215105-B2 | HPK1 antagonists and uses thereof | PDXK, HIPK1, PCK1 | SIGMAR1 3385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.